Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
European Urology|January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the BladderAndrea Necchi, Russell Madison, Daniele Raggi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classesJ H Chung, E Sanford, A Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular TestingAlexa B Schrock, Garrett M Frampton, Dana Herndon, et al.
JCO Precision Oncology|September 14, 2020
Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular TargetsErik A Williams, Adrienne J Werth, Radwa Sharaf, et al.
JCO Precision Oncology|September 11, 2020
<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent AlterationsYuri Sheikine, Dean Pavlick, Samuel J Klempner, et al.
Cancer|December 7, 2021
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instabilityStefania Bellone, Dana M Roque, Eric R Siegel, et al.
The Oncologist|June 2, 2016
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationSiraj M Ali, Thomas Hensing, Alexa B Schrock, et al.
Cancer Discovery|May 15, 2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitorsGarrett M Frampton, Siraj M Ali, Mark Rosenzweig, et al.
Nature Communications|May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Cell|October 24, 2017
Comprehensive Analysis of Hypermutation in Human CancerBrittany B Campbell, Nicholas Light, David Fabrizio, et al.
Pageof 16